Dynamic and Continuous Monitoring of Renal and Hepatic Functions with Exogenous Markers

Achilefu, Samuel; Dorshow, Richard B.

doi:10.1007/3-540-46009-8_2

Cited by 5 publications

(4 citation statements)

References 226 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been used in optical imaging of changes in blood-brain barrier permeability after thrombus formation in a mouse model of cerebral venous thrombosis [ 20 ] and liver perfusion in mouse [ 21 ]. Clinically, ICG has been used in clinical retinal angiography [ 22 ], hepatic function testing [ 23 ] and imaging of human brain [ 24 , 25 ]. Since ICG binds tightly to plasma proteins and becomes confined to the vascular system, they are widely used for intraoperative assessment of vascular flow in cardiovascular surgery [ 26 , 27 , 28 ].…”

Section: Small Organic Fluorophoresmentioning

confidence: 99%

Near-Infrared Fluorescent Nanoprobes for in Vivo Optical Imaging

Quek

Leong

2012

Nanomaterials

View full text Add to dashboard Cite

Near-infrared (NIR) fluorescent probes offer advantages of high photon penetration, reduced light scattering and minimal autofluorescence from living tissues, rendering them valuable for noninvasive mapping of molecular events, assessment of therapeutic efficacy, and monitoring of disease progression in animal models. This review provides an overview of the recent development of the design and optical property of the different classes of NIR fluorescent nanoprobes associated with in vivo imaging applications.

show abstract

Section: Small Organic Fluorophoresmentioning

confidence: 99%

Near-Infrared Fluorescent Nanoprobes for in Vivo Optical Imaging

Quek

Leong

2012

Nanomaterials

View full text Add to dashboard Cite

show abstract

“…Different dynamic liver tests using probe substances (e.g. indocyanine green, galactose, cholate, aminopurine, methacetin, caffeine, and lidocaine) might be used in order to predict hepatic metabolic function, since the liver volume could overestimate liver function [4] [5] [6] [7] . Lidocaine (LID) undergoes extensive hepatic biotransformation (around 97%) via cytochrome P (CYP) 3A4 and 1A2 to monoethylglycinexylidide (MEGX) and 3-hydroxylidocaine [8] [9] [10] .…”

Section: Introductionmentioning

confidence: 99%

Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver

Jovanović¹,

Kovačević²,

Kovačević³

et al. 2023

J Med Biochemistry

View full text Add to dashboard Cite

Background The study aimed to estimate lidocaine (LID) pharmacokinetic parameter values in patients with impaired liver function, and to assess change in parameters related to the surgical intervention. Methods Patients with impaired liver function were subject to the test prior to, 3 and 7 days after the intervention. LID was administered in single i.v. dose of 1 mg/kg. Blood samples were collected at 15, 30 and 90 minutes after drug administration. Non-compartmental analysis was applied for calculating the pharmacokinetic parameters. Results The study included 17 patients with the diagnosis of cirrhosis and 41 patients with liver tumor. In both groups of patients, the values of the coefficients of correlation show the best correlation between CL and Child-Pugh score (-0.693, p<0.005) over other pharmacokinetic parameters. The results indicate worsening hepatic function on 3rd day after operation in comparison to the values of LID CL prior to operation (mean LID CL for patients with Child-Pugh class A are 25.91 L/h, 41.59 L/h, respectively; while for B class are 16.89 L/h, 22.65 L/h, respectively). On day 7th, the values of LID CL (mean value for patients with Child-Pugh class A and B are 40.98 L/h and 21.46 L/h, respectively) are increased in comparison to 3rd day after. Conclusions LID pharmacokinetic parameters consequently changed according to the severity of liver impairment, assessed by Child-Pugh score. Values of LID CL and Vd coupled with standard biochemical parameters may be used in obtaining the complete picture of hepatic status of patients.

show abstract

“…As discussed before, researchers attempting to model pharmacokinetic behavior often choose to start with the simplest model that is theoretically sound for a given set of experimental data, and progress to more complicated models as needed based on fit results. In our case, literature shows that ICG pharmacokinetics have been modeled by other authors with either a one-compartment or a two-compartment model approach (Achilefu et al, 2002). Given these sources, there is justification to attempt to fit the data for ICG, IR820, and IRPDcov to monoexponential and biexponential curves as an initial approach.…”

Section: Pharmacokinetic Analysis Of Plasma Datamentioning

confidence: 99%

IR820 Nanoconjugates for Theranostic Applications

Fernandez-Fernandez¹

View full text Add to dashboard Cite

Dynamic and Continuous Monitoring of Renal and Hepatic Functions with Exogenous Markers

Cited by 5 publications

References 226 publications

Near-Infrared Fluorescent Nanoprobes for in Vivo Optical Imaging

Near-Infrared Fluorescent Nanoprobes for in Vivo Optical Imaging

Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver

IR820 Nanoconjugates for Theranostic Applications

Contact Info

Product

Resources

About